Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MEI Pharma ( (MEIP) ) has issued an update.
On September 3, 2025, MEI Pharma, Inc. entered into a master loan agreement with BitGo Prime, LLC, allowing the company to borrow digital assets or cash. This agreement outlines the terms for each loan, including interest rates, collateral requirements, and termination conditions. The agreement is secured by collateral, which must exceed the borrowed amount, and failure to maintain sufficient collateral can lead to default and liquidation of pledged assets.
Spark’s Take on MEIP Stock
According to Spark, TipRanks’ AI Analyst, MEIP is a Neutral.
MEI Pharma’s overall stock score is low, primarily due to significant financial performance challenges and poor valuation metrics. Weak revenue and profitability, declining asset base, and negative cash flow contribute to a fragile financial position. Additionally, technical indicators suggest a bearish trend, further impacting investor sentiment. Without clear guidance or positive corporate events, the stock’s outlook remains unfavorable.
To see Spark’s full report on MEIP stock, click here.
More about MEI Pharma
Average Trading Volume: 1,152,743
Technical Sentiment Signal: Buy
Current Market Cap: $159.3M
See more insights into MEIP stock on TipRanks’ Stock Analysis page.